Wells Fargo Report Shows GLP-1s Reducing Bariatric Surgery Rates
According to a Wells Fargo report, the surge in GLP-1 drug usage has dramatically reduced bariatric surgery rates by over 30%, offering patients a less invasive alternative for weight management. GLP-1 adoption more than doubled between 2022 and 2024, creating new opportunities for the healthcare industry to pivot toward medication management and side effect mitigation services.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- BloombergTrace: Center
Wells Fargo Report Says GLP-1s Reducing Certain Surgeries
A Wells Fargo report indicates that GLP-1 medications have significantly disrupted the bariatric surgery market, reducing procedures by over 30% as patients opt for this less invasive pharmaceutical alternative for weight management. GLP-1 usage has surged 120% between 2022 and 2024, fundamentally shifting how the healthcare industry approaches weight loss treatment. This trend presents new opportunities for healthcare providers to pivot toward medication management and side effect mitigation services.
Rate outletRead original
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
Comments
0No comments yet. Say what you noticed in the coverage.